<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02314676</url>
  </required_header>
  <id_info>
    <org_study_id>GenSci 004 CT</org_study_id>
    <nct_id>NCT02314676</nct_id>
  </id_info>
  <brief_title>Phase IV Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat Growth Hormone Deficiency Children</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>GeneScience Pharmaceuticals Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GeneScience Pharmaceuticals Co., Ltd.</source>
  <brief_summary>
    <textblock>
      This study evaluates the safety and efficiency of Pegylated Somatropin (PEG Somatropin)&#xD;
      Injection in the treatment of endogenous growth hormone deficiency (GHD) in the broad&#xD;
      population of children. Half of participants will receive the high dose, while the other half&#xD;
      will receive the low dose.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2014</start_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Actual height of the patient after treatment compared with the mean height of the population and the standard deviation (SD) of the height of the population for that chronological age</measure>
    <time_frame>26 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">900</enrollment>
  <condition>Dwarfism, Pituitary</condition>
  <arm_group>
    <arm_group_label>PEG-somatropin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PEG-somatropin</intervention_name>
    <arm_group_label>PEG-somatropin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Before starting treatment, according to the medical history, clinical symptoms and&#xD;
             signs, GH stimulation test and imaging examination, patients are diagnosed as GHD.&#xD;
&#xD;
          -  According to the height statistical data of Chinese children's physique development in&#xD;
             nine cities in 2005, height is lower than the third percentile of growth curve of&#xD;
             normal children with the same age and gender.&#xD;
&#xD;
          -  Height velocity (HV) ≤5.0 cm/yr.&#xD;
&#xD;
          -  GH stimulation test with two different mechanisms affirms that GH peak concentration&#xD;
             of patients' plasma &lt;10.0ng/ml.&#xD;
&#xD;
          -  Bone age (BA) ≤9 years in girls and ≤10 years in boys, at least 1 year less than&#xD;
             his/her chronological age (CA).&#xD;
&#xD;
          -  Be in preadolescence (Tanner stage 1) and have a CA ≧ 3 years.&#xD;
&#xD;
          -  Receive no prior GH treatment within 6 months.&#xD;
&#xD;
          -  Sign informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  People with abnormal liver or kidney function (ALT&gt; 2 times the upper limit of normal&#xD;
             value, Cr&gt; the upper limit of normal value).&#xD;
&#xD;
          -  Patients positive for hepatitis B core antigen (HBc), hepatitis B surface antigen&#xD;
             (HBsAg) or hepatitis B e antigen (HBeAg).&#xD;
&#xD;
          -  People with known highly allergic constitution or allergy to the drug of the study.&#xD;
&#xD;
          -  People with severe cardiopulmonary, hematological and malignant tumors diseases or&#xD;
             general infection and immune deficiency.&#xD;
&#xD;
          -  Potential tumor patients (family history).&#xD;
&#xD;
          -  Diabetic.&#xD;
&#xD;
          -  Abnormal growth and development, such as Turner syndrome, constitutional delay of&#xD;
             growth and puberty, Laron syndrome, growth hormone receptor deficiency, girls of&#xD;
             growth retardation without excluding abnormal chromosome.&#xD;
&#xD;
          -  Subjects took part in other clinical trial study within 3 months.&#xD;
&#xD;
          -  Other conditions which in the opinion of the investigator preclude enrollment into the&#xD;
             study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Junfen Fu, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Affiliated to Medical College of Zhejiang University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Junfen Fu, Ph.D</last_name>
    <phone>13777457849</phone>
    <email>fjf68@qq.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>First People's Hospital of Wuhu</name>
      <address>
        <city>Wuhu</city>
        <state>Anhui</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiayan Pan</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Affiliated to Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Junfen Fu, Ph.D</last_name>
      <phone>13777457849</phone>
      <email>fjf68@qq.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <study_first_submitted>November 27, 2014</study_first_submitted>
  <study_first_submitted_qc>December 9, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2014</study_first_posted>
  <last_update_submitted>December 9, 2014</last_update_submitted>
  <last_update_submitted_qc>December 9, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 11, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dwarfism</mesh_term>
    <mesh_term>Dwarfism, Pituitary</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

